ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

News provided by
ReNAgade Therapeutics
February 23, 2024 14:10 Korea Standard Time

CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m. ET.

A webcast of the event will be available in the “News” section of the Company’s website at A replay of the webcast will be archived on the Company’s website for 90 days following the presentation date.

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit

View source version on


View Korean version of this release


ReNAgade Therapeutics
Investor Relations
Argot Partners
Emily Brabbit
(212) 600-1902

Media Relations
Argot Partners
Sarah Sutton
(212) 600-1902

This is a news release distributed by Korea Newswire on behalf of this company.